|
Real-time Estimate
Cboe BZX
22:30:16 29/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 22.14 USD | -3.88% |
|
+1.07% | +26.28% |
| 10-27 | Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading | MT |
| 10-26 | Zai Lab's Lung Cancer Drug Achieves Promising Response Rate in Phase 1b Trial; Shares up 4% | MT |
Company Valuation: Zai Lab Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 6,059 | 2,946 | 2,688 | 2,853 | 1,962 | 2,587 | - | - |
| Change | - | -51.37% | -8.77% | 6.15% | -31.23% | 31.84% | - | - |
| Enterprise Value (EV) 1 | 4,650 | 1,938 | 1,897 | 2,095 | 1,397 | 2,129 | 2,206 | 2,349 |
| Change | - | -58.33% | -2.13% | 10.47% | -33.34% | 52.44% | 3.61% | 6.49% |
| P/E | -8.29x | -6.63x | -7.9x | -10.1x | -11x | -10.4x | -10.4x | -15.8x |
| PBR | 4.35x | - | 3.34x | 3.36x | 2.73x | 5.03x | 6.61x | 6.08x |
| PEG | - | 0.2x | 0.3x | 0.4x | 0.3x | -0.3x | -51.63x | 0.5x |
| Capitalization / Revenue | 42x | 13.7x | 10.1x | 7.15x | 4.26x | 5.98x | 4.72x | 3.62x |
| EV / Revenue | 32.2x | 9.01x | 7.11x | 5.25x | 3.04x | 4.92x | 4.02x | 3.29x |
| EV / EBITDA | -6.7x | -4.89x | -5.3x | -7.75x | -6.51x | -7.54x | -9.27x | -17.1x |
| EV / EBIT | -6.64x | -4.79x | -5.17x | -7.43x | -6.09x | -7.48x | -9.36x | -14.3x |
| EV / FCF | -8.19x | -4.94x | -9.23x | -9.5x | -8.5x | -12.1x | -12.3x | -19.3x |
| FCF Yield | -12.2% | -20.2% | -10.8% | -10.5% | -11.8% | -8.24% | -8.1% | -5.19% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7.58 | -4.63 | -3.46 | -2.6 | -1.6 | -2.209 | -2.214 | -1.46 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 144.3 | 215 | 266.7 | 399 | 460.2 | 432.7 | 548.2 | 713.6 |
| EBITDA 1 | -693.6 | -396.1 | -357.5 | -270.3 | -214.4 | -282.2 | -238 | -137 |
| EBIT 1 | -700.1 | -404.4 | -366.6 | -282.1 | -229.4 | -284.6 | -235.8 | -164.5 |
| Net income 1 | -704.5 | -443.3 | -334.6 | -257.1 | -175.5 | -240.7 | -219.6 | -157.1 |
| Net Debt 1 | -1,409 | -1,008 | -791.3 | -757.9 | -565.3 | -457.7 | -380.8 | -237.7 |
| Reference price 2 | 62.85 | 30.70 | 27.33 | 26.19 | 17.64 | 23.04 | 23.04 | 23.04 |
| Nbr of stocks (in thousands) | 96,409 | 95,972 | 98,349 | 108,937 | 111,219 | 112,266 | - | - |
| Announcement Date | 01/03/22 | 01/03/23 | 27/02/24 | 27/02/25 | 26/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -10.43x | 4.92x | -7.54x | -.--% | 2.59B | |
| 37.84x | 13.27x | 28.43x | 0.53% | 1,148B | |
| 39.67x | 6.67x | 18.75x | 1.97% | 652B | |
| 37.4x | 8.39x | 17.35x | 2.4% | 505B | |
| 21.45x | 5.21x | 12.93x | 2.51% | 384B | |
| 102.73x | 5.76x | 24.72x | 2.42% | 348B | |
| 21.89x | 5.76x | 13.88x | 2.85% | 294B | |
| 22.21x | 4.49x | 12.82x | 1.97% | 264B | |
| 28.66x | 7.33x | 13.12x | 2.23% | 244B | |
| -45.79x | 7.11x | 27.55x | 2.07% | 197B | |
| Average | 25.56x | 6.89x | 16.20x | 1.9% | 403.97B | |
| Weighted average by Cap. | 35.26x | 8.39x | 20.62x | 1.79% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ZLAB Stock
- Valuation Zai Lab Limited
Select your edition
All financial news and data tailored to specific country editions
